Personalized Medicine

Genomics, proteomics and AI converge in personalised medicine with growing routine-care implementation. The session covers polygenic risk scores in primary prevention (cardiovascular, type 2 diabetes), pharmacogenomics in oncology (HER2-low, MSI-H, TMB), CYP-based pharmacogenomic prescribing in psychiatry, biomarker-driven trials and basket designs, multi-omics integration into clinical decision support, and liquid biopsy in MRD detection. Discussion addresses the equity and bias challenges in genomic medicine, the integration of polygenic risk scores into UK Biobank-style population-screening pilots, the regulatory framework for AI-driven personalised medicine, and the implementation gap between research and routine clinical use.